

## HUTCHMED

### Fruquintinib clinical and commercial updates

12 February 2024

- Data from the Phase III [FRUTIGA](#) trial of fruquintinib in combination with paclitaxel for the treatment of 2L (second-line) advanced gastric cancer (GC) or gastro-esophageal junction adenocarcinoma (GEJ) in China were presented at the American Society of Clinical Oncology (ASCO) Plenary Series Session. These data supported the China NDA submission for fruquintinib in this setting, which was accepted for review in April 2023.
- FRUTIGA was a 1:1 randomised, double-blind, 703 patient Phase III study carried out at 35 sites in China evaluating fruquintinib in combination with paclitaxel vs paclitaxel monotherapy for treatment of advanced GC or GEJ. It met one of the dual primary endpoints: progression-free survival (PFS) with median PFS of 5.6 months for combination therapy vs 2.7 months for paclitaxel monotherapy (HR = 0.569;  $p < 0.0001$ ). Improvement in overall survival (OS), the other primary endpoint, was numerically but not statistically significant; pre-specified sensitivity analyses indicated this was likely due to an imbalance of patients receiving subsequent antitumour therapies across both arms. Improvements in secondary endpoints included objective response rate (ORR: 42.5% vs 22.4%), disease control rate (DCR: 77.2% vs 56.3%) and duration of response (DoR: 5.5 vs 3.7 months). Fruquintinib plus paclitaxel was well tolerated, with a safety profile consistent with prior studies.
- Assuming a positive approval decision in 2024, 2L GC/GEJ would be the second indication for fruquintinib in China. It is already approved in advanced metastatic colorectal cancer (mCRC) as a monotherapy in China and the US, and is currently under review for advanced mCRC in Europe and Japan, with approval decisions anticipated in 2024.
- Separately, global ex-China partner Takeda provided first insights into the US launch of fruquintinib (FRUZAQLA) for previously treated mCRC. Given the unmet need, it was made commercially available in November 2023 within 24 hours of FDA approval, and initial uptake has been strong. We note that FRUZAQLA is not yet a separate revenue line item but is included in 'Oncology Others'; Takeda reported Oncology Others sales of JPY3.3bn for Q324 (October-December 2023) vs JPY0.9bn for Q224.

**Trinity Delta view:** Fruquintinib's commercial prospects are a key contributor to HUTCHMED's path to profitability, which is supported by the growing traction and market share capture of its China oncology products, additional potential approvals and launches (by partner Takeda) of fruquintinib in international markets, and a solid balance sheet. Fruquintinib's potential approval in a second indication in China (2L gastric cancer) as well as tiered royalties on annual net sales in Takeda's markets (undisclosed but assumed to start from mid-teens) should drive significant future revenues. Nearer-term, the revenues from HUTCHMED's three marketed oncology products in China, coupled with partial recognition (\$280m) of the Takeda licence upfront contribute to FY23 revenue guidance of \$450-550m. FY23 results will report on February 28. Our last published valuation is \$5.74bn/ £4.78bn/ HK\$44.75bn, or \$32.95/ADS and 549p/HK\$51.40 per share.

Price (US ADS)	\$14.01
(UK share)	221.0p
(SEHK share)	HK\$21.80
Market Cap	US\$2.42bn £1.93bn HK\$19.12bn
Exchanges	NASDAQ AIM London SEHK
Sector	Healthcare
Company codes	HCM HCM.L 0013.HK
Corporate client	Yes

#### Company description:

HUTCHMED is a Hong Kong headquartered biopharma focused on discovering, developing and commercialising innovative targeted therapeutics and immunotherapies to treat cancer and autoimmune diseases. It has a diverse pipeline of first-in-class/best-in-class selective oral TKIs in development for the China and global markets.

#### Analysts

##### Lala Gregorek

lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

##### Philippa Gardner

pgardner@trinitydelta.org  
+44 (0) 20 3637 5042

**Philippa Gardner**

[pgardner@trinitydelta.org](mailto:pgardner@trinitydelta.org)  
+44 (0) 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)  
+44 (0) 20 3637 5043

**Franc Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)  
+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)